Product Details
| Product Name:
IMM-H007 |
CAS No.:
1221412-23-2 |
| Purity:
97.73% |
Supply Ability:
10g |
| Release date:
2025/07/25 |
Product Introduction
Bioactivity
| Name | IMM-H007 |
| Description | IMM-H007 is a novel lipid-lowering agent, increasing abca1 protein expression |
| In vitro | IMM-H007 (H007) significantly inhibits monocyte adhesion to endothelial cells and its transendothelial migration.?Mechanistically, H007 markedly represses TNFα-induced IκBα degradation and NF-κB nuclear translocation, therefore leading to NF-κB-mediated inflammatory suppression.?Moreover, another inflammatory signaling JNK/c-Jun, which is always co-activated with NF-κB in response to pro-inflammatory stimuli, is also found to be restrained by H007 through reducing its phosphorylation status.?H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 22.5 mg/mL (46.35 mM), Sonication is recommended.
|
| Keywords | WS-070117 | WS070117 | WS 070117 | Transforming growth factor beta receptors | TGF-β Receptor | Nuclear factor-κB | Nuclear factor-kappaB | Nonalcoholic fatty liver disease | NF-κB | NAFLD | JNK/c-Jun | JNK | Inhibitor | inhibit | inflammatory | IMM-H-007 | IMM-H007 | IMMH007 | IMM-H 007 | IMM H007 | HIFProlylHydroxylase | HIF/HIFProlylHydroxylase | HIF/HIF ProlylHydroxylase | HIF Prolyl-Hydroxylase | HIF ProlylHydroxylase | HIF | cardiac fibrosis | atherosclerosis | AP-1 | AMPK | AMP-activated protein kinase | Activator Protein 1 |
| Inhibitors Related | Deferoxamine Mesylate | Hydralazine hydrochloride | 1,4-DPCA | Chlorogenic Acid | Glucosamine | Hydroxycitric acid tripotassium hydrate | Glucosamine hydrochloride | Minocycline hydrochloride | Chloramphenicol | Oltipraz | Albendazole | Glucosamine sulfate |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Glutamine Metabolism Compound Library | Hematonosis Compound Library | Angiogenesis related Compound Library | Neuroprotective Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Transcription Factor-Targeted Compound Library | Nucleotide Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:264218-23-7
$40.00 / 5mg
-
CAS:218795-74-5
$44.00 / 1mg
-
CAS:138661-03-7
$65.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-07-19 |
United States